WALLSTENT ENDOPROSTHESIS
Received Jan 30, 2025 · Event occurred Nov 21, 2024
Report 2124215-2025-02341 · MDR key 21277039
Device
Generic name
Catheter, Biliary, Diagnostic
Manufacturer
Boston Scientific CorporationModel number
26280Catalog number
26280
Lot number
0032722174
Product problems
- Positioning Failure
- Difficult to Remove
- Positioning Failure
- Difficult to Remove
Patient
71 YR · Male
- No Clinical Signs, Symptoms or Conditions
- No Clinical Signs, Symptoms or Conditions
Narrative
Description of Event or Problem
IT WAS REPORTED THAT THE DEVICE WAS DIFFICULT TO REMOVE. THE TARGET LESION WAS LOCATED IN THE ILIAC VEIN. A 12X90/8FR WALLSTENT ENDOPROSTHESIS SELF-EXPANDING STENT WAS SELECTED FOR TREATMENT. DURING THE PROCEDURE, IT WAS NOTED THAT THE STENT COULD NOT BE DEPLOYED, AND IT WAS DIFFICULT TO WITHDRAW. THE PROCEDURE WAS NOT COMPLETED. NO COMPLICATIONS WERE REPORTED, AND THE PATIENT WAS STABLE POST PROCEDURE.
Description of Event or Problem
IT WAS REPORTED THAT THE DEVICE WAS DIFFICULT TO REMOVE. THE TARGET LESION WAS LOCATED IN THE ILIAC VEIN. A 12X90/8FR WALLSTENT ENDOPROSTHESIS SELF EXPANDING STENT WAS SELECTED FOR TREATMENT. DURING THE PROCEDURE, IT WAS NOTED THAT THE STENT COULD NOT BE DEPLOYED, AND IT WAS DIFFICULT TO WITHDRAW. THE PROCEDURE WAS NOT COMPLETED. NO COMPLICATIONS WERE REPORTED, AND THE PATIENT WAS STABLE POST PROCEDURE. IT WAS FURTHER REPORTED THAT THE PATIENT WAS UNDER LOCAL ANESTHESIA. THE TARGET LESION WAS LOCATED 70% STENOSED, MODERATELY TORTUOUS AND MODERATELY CALCIFIED. THE STENT WAS NORMALLY RECAPTURED INTO THE CATHETER.
Additional Manufacturer Narrative
THE DEVICE WAS RETURNED FOR EVALUATION. THE DEVICE WAS RECEIVED WITH THE STENT FULLY CONSTRAINED IN THE CORRECT POSITION ON THE DEVICE. THE INVESTIGATOR SUCCESSFULLY DEPLOYED THE STENT WITH NO RESISTANCE EXPERIENCED. A VISUAL EXAMINATION IDENTIFIED NO ISSUES OR DAMAGE TO THE DEPLOYED STENT. A VISUAL AND TACTILE EXAMINATION IDENTIFIED NO DAMAGE OR ISSUES WITH THE TIP OR DELIVERY SYSTEM. NO OTHER ISSUES WERE IDENTIFIED DURING THE PRODUCT ANALYSIS.